These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 17571365

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
    Pagani ED, Dundore RL, Bode DC, Bacon ER, Singh B, Lesher GY, Buchholz RA, Silver PJ.
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
    [Abstract] [Full Text] [Related]

  • 5. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
    Gold J, Cullinane S, Chen J, Seo S, Oz MC, Oliver JA, Landry DW.
    Am J Cardiol; 2000 Feb 15; 85(4):506-8, A11. PubMed ID: 10728962
    [Abstract] [Full Text] [Related]

  • 6. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
    Murray KJ, England PJ.
    Biochem Soc Trans; 1992 May 15; 20(2):460-4. PubMed ID: 1327922
    [No Abstract] [Full Text] [Related]

  • 7. [Levosimendan].
    Michels G, Herzig S, Hoppe UC.
    Dtsch Med Wochenschr; 2005 Oct 28; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract] [Full Text] [Related]

  • 8. [The effect of milrinone administrated before weaning from cardiopulmonary bypass in adult cardiac surgery].
    Hibino N, Tomino T, Satoh H, Hamawaki M, Imura M, Suzuki T, Inukai M.
    Kyobu Geka; 2000 Nov 28; 53(12):1019-23. PubMed ID: 11079307
    [Abstract] [Full Text] [Related]

  • 9. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
    Dundore RL, Pagani ED, Bode DC, Bacon ER, Singh B, Lesher GY, Buchholz RA, Silver PJ.
    J Cardiovasc Pharmacol; 1995 Jan 28; 25(1):14-21. PubMed ID: 7723343
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Basic and clinical characteristics of PDE 3 inhibitors as cardiotonic agents.
    Endoh M.
    Cardiovasc Drugs Ther; 2007 Jun 28; 21(3):135-9. PubMed ID: 17508272
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
    de Cheffoy de Courcelles D, de Loore K, Freyne E, Janssen PA.
    J Pharmacol Exp Ther; 1992 Oct 28; 263(1):6-14. PubMed ID: 1328613
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of phosphodiesterase III with milrinone increases renin secretion in human subjects.
    Chiu YJ, Hu SH, Reid IA.
    J Pharmacol Exp Ther; 1999 Jul 28; 290(1):16-9. PubMed ID: 10381754
    [Abstract] [Full Text] [Related]

  • 14. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
    Thomas RE, Armstrong DT, Gilchrist RB.
    Dev Biol; 2002 Apr 15; 244(2):215-25. PubMed ID: 11944932
    [Abstract] [Full Text] [Related]

  • 15. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A, Ono K, Sato Y, Shioi T, Nose Y, Sasayama S.
    J Mol Cell Cardiol; 1996 Dec 15; 28(12):2491-9. PubMed ID: 9004165
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
    Kieback AG, Iven H, Stolzenburg K, Eichner E, Ruckdeschel W, Baumann G.
    Int J Cardiol; 2003 Oct 15; 91(2-3):201-8. PubMed ID: 14559131
    [Abstract] [Full Text] [Related]

  • 17. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P, Parry G, Dark JH, Macgowan GA.
    J Heart Lung Transplant; 2009 Jul 15; 28(7):676-82. PubMed ID: 19560695
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of chronic pulmonary thromboembolism by long-term intermittent administration of milrinone, a phosphodiesterase-ill inhibitor.
    Sonoda K, Ikeda S, Miyahara Y, Kohno S.
    Intern Med; 2002 Nov 15; 41(11):961-6. PubMed ID: 12487168
    [Abstract] [Full Text] [Related]

  • 19. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
    Beierwaltes WH.
    Am J Physiol Renal Physiol; 2006 Jun 15; 290(6):F1376-81. PubMed ID: 16449359
    [Abstract] [Full Text] [Related]

  • 20. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P, Prigent AF, Lagarde M, Nemoz G.
    Mol Pharmacol; 1993 Nov 15; 44(5):1027-35. PubMed ID: 8246905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.